Home Newsfeeds Compass Point Downgrades HarborOne Bancorp to Neutral, Announces $14 Price Target

Compass Point Downgrades HarborOne Bancorp to Neutral, Announces $14 Price Target

Compass Point analyst Laurie Havener downgrades HarborOne Bancorp (NASDAQ:HONE) from Buy to Neutral and announces $14 price target.

byBenzinga Newsdesk

October 20, 2022

1 minute read

Compass Point analyst Laurie Havener downgrades HarborOne Bancorp (NASDAQ:HONE) from Buy to Neutral and announces $14 price target.

Analyst Ratings

Analyst Ratings for Chewy

By Benzinga Insights

December 15, 2:00 PM

Chewy (NYSE:CHWY) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

CHWY

Global
News

YY Group Announces Strategic Entry Into Vietnam’s Booming Labour Market Within The Hospitality Industry

By Benzinga Newsdesk

May 2, 8:39 AM

YY Group Holding Limited (NASDAQ: YYGH) ("YY Group", "YYGH", or the "Company"), a data and technology-driven company that specializes in creating enterprise intelligent labor matching services and smart cleaning

YYGH

Robinhood Lowered Its Offer to Acquire London-based Crypto Exchange Ziglu from $170M to $72.5M

By Charles Gross

August 19, 5:36 AM

-Blockworks https://blockworks.co/robinhood-slashes-offer-to-buy-crypto-exchange-ziglu-by-60/

HOOD

Provention Bio’s $2.9B Acquisition – A Strategic Fit For Sanofi

By Vandana Singh

March 13, 11:04 AM

Sanofi SA (NASDAQ:SNY) has agreed to acquire Provention Bio Inc (NASDAQ:PRVB) for $25.00 per share in cash, representing an equity value of approximately…

PRVB

Compass Point Downgrades HarborOne Bancorp to Neutral, Announces $14 Price Target

Related Posts

Analyst Ratings for Chewy

YY Group Announces Strategic Entry Into Vietnam’s Booming Labour Market Within The Hospitality Industry

Robinhood Lowered Its Offer to Acquire London-based Crypto Exchange Ziglu from $170M to $72.5M

Provention Bio’s $2.9B Acquisition – A Strategic Fit For Sanofi